Autopsy report · NCT00496756

Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer

“Low accrual rate”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months after it had already started.
• Ran for about 7 years 2 months before it stopped.
• 14 participants enrolled.
• Results were posted on the registry 4 years 10 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

University of Nebraska

Sponsor type

University, hospital or other

Conditions

Kidney Cancer

Interventions

Sorafenib

Participants

14

Sites

1

Countries

United States

Trials that died the same way

• A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI
  “Poor accrual rate” (92% match in meaning)
• Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast Cancer
  “Accrual rate was too low” (88% match in meaning)
• Antiretroviral Improvement Among Medicaid Enrollees
  “Insufficient rate of accrual” (87% match in meaning)
• Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy
  “insufficient accrual rate” (85% match in meaning)
• UVB Phototherapy Treatment of Oral Chronic GVHD
  “Low/slow accrual” (84% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.